Sort   by:  
 Page size 
UnknownEffect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis.
Not available
S-EPMC8184698 | biostudies-literature
UnknownPerineal wound complications after total neoadjuvant therapy or chemoradiotherapy followed by abdominoperineal excision in patients with high-risk locally advanced rectal cancer in the RAPIDO trial.
Not available
S-EPMC12022605 | biostudies-literature
UnknownAdjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis.
Not available
S-EPMC9857200 | biostudies-literature
UnknownSystemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry.
Not available
S-EPMC9688066 | biostudies-literature
UnknownSurgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy.
Not available
S-EPMC7281176 | biostudies-literature
UnknownSex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study.
Not available
S-EPMC8465427 | biostudies-literature
UnknownSwitching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?
Not available
S-EPMC6966631 | biostudies-literature
UnknownCheckpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients.
Not available
S-EPMC8144142 | biostudies-literature
UnknownImproving survival in advanced melanoma patients: a trend analysis from 2013 to 2021.
Not available
S-EPMC10874714 | biostudies-literature
UnknownTumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma.
Not available
S-EPMC11262179 | biostudies-literature
Sort   by:  
 Page size